Professor Hans Prenen from University Hospital Antwerp, Belgium addresses the clinical question ‘What is the future of immunotherapy in colorectal cancer?’
Professor Hans Prenen from University Hospital Antwerp, Belgium addresses the clinical question ‘What is the future of immunotherapy in colorectal cancer?’
Hans Prenen obtained his medical degree and PhD at the Catholic University Leuven. He is currently the head of the Medical Oncology Department at the University Hospital Antwerp and director of the Oncology Clinical Trial Unit. He is member of several scientific organisations including the Belgian Society of Medical Oncology (board member since 2015) and the European Society of Medical oncology (scientific committee). He is a recognised international expert in the field of cancer and is regularly invited to national and international meetings and has published more than 200 peer reviewed scientific papers. He is principal investigator of several clinical trials with a focus on phase 1 and basket trials. His research interests relate to translational studies on targeted therapies, new anticancer therapies and understanding the molecular changes induced by anticancer therapy.
Optimising precision medicine for improved patient outcomes
A closer look at the evolving treatment landscape
Experts' insights on treatment strategies in ER+ metastatic breast cancer settings
Expert insights on multimodal treatment for intermediate hepatocellular carcinoma (HCC)
Best practices and interpretation of results in lung and ovarian cancer
Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer